World Outcomes After First
A retrospective study of lung cancer patients suggests that the effectiveness of first-line osimertinib treatment is heavily influenced by whether patients receive subsequent therapy. The findings highlight the need for better strategies in managing EGFR-mutant NSCLC after initial treatment failure.
Why it matters
Understanding real-world treatment outcomes is critical for oncologists to improve survival rates and optimize therapy sequences for metastatic cancer patients.
Yan Leyfman , Medical Oncologist, Co-Founder and Executive Director of MedNews Week, shared on LinkedIn :
“What happens to patients with EGFR – mutant lung cancer after first-line osimertinib stops working? The FLAURA2 trial established that adding chemotherapy to osimertinib improves overall survival in metastatic EGFR-mutant NSCLC .
But one important question remains: how much of that benefit is influenced by what happens after first-line therapy?
A retrospective study of 115 patients treated with first-line osimertinib monotherapy at a U.S. academic medical center offers a sobering real-world perspective.
Among the 66 patients who discontinued osimertinib :
The study also highlights the heterogeneity of EGFR-mutant disease.
Median time to treatment failure was:25.3 months overallBut only 15.7 months for patients with TP53-mutant tumors versus 42.2 months for TP53 wild-type disease.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in